NCT05828212View on ClinicalTrials.gov

Evaluate the Safety and Efficacy of CAR-T Cells in the Treatment of R/R Neuromyelitis Optica

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

May 15, 2023

Primary Completion Date

July 30, 2025

Study Completion Date

July 30, 2025

Conditions
Neuromyelitis Optica
Interventions
DRUG

CAR-T cells injection

CAR-T cells in the treatment of R/R neuromyelitis optica

Trial Locations (1)

310000

The first affiliated hospital of medical college of zhejiang university, Hangzhou

All Listed Sponsors
collaborator

Yake Biotechnology Ltd.

INDUSTRY

lead

Zhejiang University

OTHER

NCT05828212 - Evaluate the Safety and Efficacy of CAR-T Cells in the Treatment of R/R Neuromyelitis Optica | Biotech Hunter | Biotech Hunter